These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 7520100

  • 1. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
    Gharehbaghi K, Burgess GS, Collart FR, Litz-Jackson S, Huberman E, Jayaram HN, Boswell HS.
    Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
    [Abstract] [Full Text] [Related]

  • 2. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG, Boosalis M, Malek K, Waraska K.
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [Abstract] [Full Text] [Related]

  • 3. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
    Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS.
    Blood; 1993 Sep 15; 82(6):1838-47. PubMed ID: 7691239
    [Abstract] [Full Text] [Related]

  • 4. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW, Ren R.
    Oncogene; 2000 Dec 14; 19(54):6286-96. PubMed ID: 11175343
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, Toyama K.
    Exp Hematol; 1995 Oct 14; 23(11):1153-9. PubMed ID: 7556524
    [Abstract] [Full Text] [Related]

  • 11. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
    Jayaram HN, O'Connor A, Grant MR, Yang H, Grieco PA, Cooney DA.
    J Exp Ther Oncol; 1996 Sep 14; 1(5):278-85. PubMed ID: 9414415
    [Abstract] [Full Text] [Related]

  • 12. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS, Wu Y, McMahon R, Yu L, Rossi JJ, Forman SJ.
    Biol Blood Marrow Transplant; 1997 Oct 14; 3(4):179-86. PubMed ID: 9360779
    [Abstract] [Full Text] [Related]

  • 13. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN, Ahluwalia GS, Jayaram HN, Cooney DA, Johns DG.
    J Clin Invest; 1985 Jan 14; 75(1):175-82. PubMed ID: 2856924
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
    Haematologica; 2003 Jun 14; 88(6):622-30. PubMed ID: 12801837
    [Abstract] [Full Text] [Related]

  • 16. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G, Weber G.
    Anticancer Res; 1996 Jun 14; 16(6A):3341-7. PubMed ID: 9042309
    [Abstract] [Full Text] [Related]

  • 17. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J, Arlinghaus RB.
    Oncogene; 1999 Aug 05; 18(31):4416-24. PubMed ID: 10442632
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
    Campbell ML, Li W, Arlinghaus RB.
    Oncogene; 1990 May 05; 5(5):773-6. PubMed ID: 2140598
    [Abstract] [Full Text] [Related]

  • 20. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
    Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG.
    Oncogene; 1998 Jan 29; 16(4):489-96. PubMed ID: 9484838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.